The investigations target specific equity stakes and deal terms for each company. For Non-Invasive Monitoring Systems (NIMU), current shareholders are slated to retain a 4.5% stake in the entity following its merger with Gravitics, Inc. Similarly, InMed Pharmaceuticals (INM) investors face a dilution to approximately 1.51% of the combined company after its deal with Mentari Therapeutics closes.

In the chemical sector, the firm is reviewing the Olin Corporation (OLN) and Huntsman Corporation (HUN) tie-up. Under the proposed agreement, Huntsman shareholders are set to receive 0.5476 shares of Olin for each share held, with Olin investors expected to control 54.5% of the resulting business. Monteverde & Associates, which maintains offices in the Empire State Building, is currently soliciting feedback from investors concerned about the fairness of these transactions. The firm emphasizes that these inquiries are conducted at no cost to the shareholders involved.